**8. Conclusion**

Non-viral gene therapy using the entire genomic locus of the therapeutic gene has two advantages over viral cDNA gene therapy; it is not associated with unwanted immune responses and can confer controlled levels of transgene expression in correct time and

Non-Viral Gene Therapy Vectors Carrying Genomic Constructs 19

Black, J., & Vos, JM. (2002). Establishment of an oriP/EBNA1-based episomal vector

Boucher, RC. (2002). An overview of the pathogenesis of cystic fibrosis lung disease.

Brown, PA., Khan, AS., & Draghia-Akli, R. (2008). Delivery of DNA into skeletal muscle in

Bushman, F., Lewinski, M., Ciuffi, A., Barr, S., Leipzig, J., Hannenhalli, S. & Hoffmann, C.

Caplen, NJ., Alton, EW, Middleton, PG., Dorin, JR., Stevenson, BJ., Gao, X., Durham, SR.,

Carson, S., & Wiles, MV. (1993). Far upstream regions of class II MHC Ea are necessary for

Cavazzana-Calvo, M, Hacein-Bey, S., Saint Basile, G. de Gross, F., Yvon, E., Nusbaum, P.,

Chang, M.L., Chen, JC., Yeh, CT., Chang, MY., Liang, CK., Chiu, CT., Lin, DY. & Liaw, YF.

Cohen, JI. (2000). Epstein-Barr virus infection. *New England journal of medicine*, 343(7), pp.

Copeland, NG, Jenkins, NA, & Court, DL. (2001). Recombineering: a powerful new tool for mouse functional genomics. *Nature reviews. Genetics*, 2(10), pp. 769-79. Cortés, ML, Oehmig, A., Saydam, O., Sanford, JD., Perry, KF, Fraefel, C. & Breakefield, X.

Daud, AI., DeConti, RC., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., Munster, P.,

Dean, DA., Machado-Aranda, D., Blair-Parks, K., Yeldandi, AV., & Young, JL. (2003).

Dorin, JR., Farley, R, Webb, S., Smith, SN., Farini, E., Delaney, SJ., Wainwright, B., Alton,

superficial hepatocytes. *Human gene therapy*, 19(4), pp. 391-5.

recombination. *Annual review of genetics*, 36, pp. 361-88.

103(2), pp. 419-24.

pp. 39-46.

481-92.

*therapy*, 9(21), pp. 1447-54.

*Microbiology*, 3(11), pp. 848-58.

*research*, 21(9), pp. 2065-72.

*oncology*, 26(36), pp. 5896-903.

*therapy*, 10(18), pp. 1608-15.

disease. *Science*, 288(5466), pp. 669-72.

*Advanced drug delivery reviews*, 54(11), pp. 1359-71.

large animals. *Methods in molecular biology*, 423, pp. 215-24.

directed plasmid integration. *Proceedings of the National Academy of Sciences USA*,

transcribing human genomic beta-globin in cultured murine fibroblasts. *Gene* 

(2005). Genome-wide analysis of retroviral DNA integration. *Nature reviews.* 

Jeffery, PK., Hodson, ME. & Coutelle, C. (1995). Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. *Nature medicine*, 1(1),

position-independent, copy-dependent expression of Ea transgene. *Nucleic acids* 

Seiz, F., Hue, C., Certain, S., Casanova, JL., Bousso, P., Deist, FL. & Fischer, A. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1

(2008). Gene gun bombardment with DNA-coated gold particles is a potential alternative to hydrodynamics-based transfection for delivering genes into

(2008). Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV hybrid amplicon vector. *Molecular therapy*, 16(1), pp. 81-8. Court, DL., Sawitzke, JA., & Thomason, LC. (2002). Genetic engineering using homologous

Sullivan, D., Urgen, K., Messina, J. & Heller, R. (2008). Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. *Journal of clinical* 

Electroporation as a method for high-level nonviral gene transfer to the lung. *Gene* 

EW. & Porteous, DJ. (1996). A demonstration using mouse models that successful

tissue. When combined with a system for extra-chromosomal maintenance or targeted integration it can provide permanent transgene expression without causing insertional mutagenesis and is therefore considered to be very safe. Among all available systems, the *S/MAR* element seems to be the most efficient, safe and convenient and may also be utilized *in vivo*. The problem of difficulty in manipulating large segments of DNA and in delivering them into cells *in vitro* or *in vivo*, which has been limiting the use of genomic constructs in gene therapy for years, has started finding its solution by the development of recombineering and of several physical and chemical methods for gene transfer. Apparently, there will not be a delivery system for general use and the choice of the most appropriate delivery method will depend on the specific application and gene therapy strategy.

### **9. Acknowledgements**

This work was funded by the Greek Ministry of Development-GSRT (ENTER 04EP56), the Greek Ministry of Health-KESY (70/3/10295) and the University of Athens (Kapodistrias 70/4/9913).

#### **10. References**


tissue. When combined with a system for extra-chromosomal maintenance or targeted integration it can provide permanent transgene expression without causing insertional mutagenesis and is therefore considered to be very safe. Among all available systems, the *S/MAR* element seems to be the most efficient, safe and convenient and may also be utilized *in vivo*. The problem of difficulty in manipulating large segments of DNA and in delivering them into cells *in vitro* or *in vivo*, which has been limiting the use of genomic constructs in gene therapy for years, has started finding its solution by the development of recombineering and of several physical and chemical methods for gene transfer. Apparently, there will not be a delivery system for general use and the choice of the most appropriate delivery method will depend on the specific application and gene

This work was funded by the Greek Ministry of Development-GSRT (ENTER 04EP56), the Greek Ministry of Health-KESY (70/3/10295) and the University of Athens (Kapodistrias

Abdallah, BM. & Kassem, M. (2008). Human mesenchymal stem cells: from basic biology to

Abdulrazzak, H., Moschidou, D., Jones, G. & Guillot PV. (2010). Biological characteristics of

Al-Dosari, MS. & Gao, X. (2009). Nonviral gene delivery: principle, limitations, and recent

Alter, J., Sennoga, CA., Lopes, DM., Eckersley, RJ. & Wells, DJ. (2009). Microbubble stability

Aluigi, M., Fogli, M., Curti, A., Isidori, A., Gruppioni, E., Chiodoni, C., Colombo, MP.,

Baiker, A., Maercker, C., Piechaczek, C., Schmidt, S. B., Bode, J, Benham, C. & Lipps, H.

Bertoni, C., Jarrahian, S., Wheeler, TM., Li, Y., Olivares, EC., Calos, MP. & Rando, TA.

marrow-derived mesenchymal stem cells. *Stem cells*, 24(2), pp. 454-61. Atkinson, H. & Chalmers, R. (2010). Delivering the goods: viral and non-viral gene therapy

vivo gene transfer. *Ultrasound in medicine & biology*, 35(6), pp. 976-84. Alton, EW, Middleton, PG., Caplen, NJ., Smith, SN., Steel, DM., Munkonge, FM., Jeffery,

stem cells from foetal, cord blood and extraembryonic tissues. *Journal of Royal* 

is a major determinant of the efficiency of ultrasound and microbubble mediated in

PK., Geddes, DM., Hart, SL. & Williamson, R. (1993). Non-invasive liposomemediated gene delivery can correct the ion transport defect in cystic fibrosis mutant

Versura, P., D'Errico-Grigioni, A., Ferri, E., Baccarani, M. & Lemoli, RM. (2006). Nucleofection is an efficient nonviral transfection technique for human bone

systems and the inherent limits on cargo DNA and internal sequences. *Genetica*,

(2000). Mitotic stability of an episomal vector containing a human scaffold/matrixattached region is provided by association with nuclear matrix. *Nature cell biology*,

(2006). Enhancement of plasmid-mediated gene therapy for muscular dystrophy by

clinical applications. *Gene therapy*, 15(2), pp. 109-16.

*Society Interface*, 6(7), pp. 689-706

progress. *AAPS journal*, 11(4), pp. 671-81.

mice. *Nature genetics,*Vol. 5, pp. 135-42.

138, pp. 485–498

2(3), pp. 182-4.

therapy strategy.

70/4/9913).

**10. References** 

**9. Acknowledgements** 

directed plasmid integration. *Proceedings of the National Academy of Sciences USA*, 103(2), pp. 419-24.


Non-Viral Gene Therapy Vectors Carrying Genomic Constructs 21

Harris, A, Young, BD., & Griffin, BE. (1985). Random association of Epstein-Barr virus

Heaney, JD., Rettew, AN., & Bronson, SK. (2004). Tissue-specific expression of a BAC

Heng, HQ., Goetze, S., Ye, CJ., Liu, G., Stevens, JB., Bremer, SW., Wykes, S., Bode, J. &

Hodgson, JG., Smith, DJ., McCutcheon, K., Koide, HB., Nishiyama, K., Dinulos, MB., et al.

Huang, Y., Liu, DP., Wu, L., Li, TC., Wu, M., Feng, DX., et al. (2000). Proper developmental

Huertas, D., Howe, S, McGuigan, A., & Huxley, C. (2000). Expression of the human CFTR

Hyde, S. C., Gill, D. R., Higgins, C. F., Trezise, A. E., MacVinish, L. J., Cuthbert, A. W., et al.

Ivics, Z. % Izsvak, S. (2010). The expanding universe of transposon technologies for gene

Jackson, D. A., Juranek, S., & Lipps, Hans J. (2006). Designing nonviral vectors for efficient gene transfer and long-term gene expression. *Molecular therapy*, 14(5), pp. 613-26. Kakeda, M., Hiratsuka, M., Nagata, K., Kuroiwa, Y., Kakitani, M., Katoh, M., et al. (2005).

Keravala, A., Lee, S., Thyagarajan, Bhaskar, Olivares, Eric C, Gabrovsky, V. E., Woodard, L.

Koppel, I., Aid-Pavlidis, T., Jaanson, K., Sepp, M., Pruunsild, P., Palm, K., et al. (2009).

Kotin, R. M., Linden, R. M., & Berns, K I. (1992). Characterization of a preferred site on

Kotzamanis, G., Abdulrazzak, H., Gifford-Garner, J., Haussecker, PL., Cheung, W., Grillot-

homologous recombination. *EMBO journal*, 11(13), pp. 5071-8.

cell lines. *Journal of virology*, 56(1), pp. 328-32.

83(6), pp. 1072-82.

*medicine*, 9(6), pp. 488-97.

*genetics*, 5(12), pp. 1875-85.

gene therapy. *Nature*, 362(6417), pp. 250-5.

and specificity. *Molecular therapy*, 17(1), pp. 112-20.

BAC transgenic mice. *BMC neuroscience*, 10, 68.

and cell engineering. *Mobile DNA*, 1:25

pp. 598-610.

852-6.

9(4), pp. 617-29.

genomes with host cell metaphase chromosomes in Burkitt's lymphoma-derived

transgene targeted to the Hprt locus in mouse embryonic stem cells. *Genomics,*

Krawetz, S. (2004). Chromatin loops are selectively anchored using scaffold/matrix-attachment regions. *Journal of cell science*, 117(Pt 7), pp. 999-1008. Hibbitt, OC., Harbottle, RP., Waddington, SN., Bursill, CA., Coutelle, C., Channon, KM.

&Wade-Martins, R. (2007). Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection. *Journal of gene* 

(1996). Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. *Human molecular* 

control of human globin genes reproduced by transgenic mice containing a 160-kb BAC carrying the human beta-globin locus. *Blood cells, molecules & diseases*, 26(6),

gene from episomal oriP-EBNA1-YACs in mouse cells. *Human molecular genetics*,

(1993). Correction of the ion transport defect in cystic fibrosis transgenic mice by

Human artificial chromosome (HAC) vector provides long-term therapeutic transgene expression in normal human primary fibroblasts. *Gene therapy*, 12(10), pp.

E., et al. (2009). Mutational derivatives of PhiC31 integrase with increased efficiency

Tissue-specific and neural activity-regulated expression of human BDNF gene in

human chromosome 19q for integration of adeno-associated virus DNA by non-

Courvalin, C., et al. (2009). CFTR expression from a BAC carrying the complete

gene therapy for cystic fibrosis requires only partial gene correction. *Gene therapy*, 3(9), pp. 797-801.


Eastman, SJ., Baskin, KM., Hodges, BL., Chu, Q., Gates, A., Dreusicke, R., Anderson, S. &

Fischer, D., Bieber, T., Li, Y, Elsässer, H. P., & Kissel, T. (1999). A novel non-viral vector for

Francastel, C., Walters, MC., Groudine, M., & Martin, DI. (1999). A functional enhancer

Gresch, O., Engel, F. B., Nesic, D., Tran, T., England, H., Hickman, E., Korner, I., Gan, L.,

Griesenbach, U., & Alton, EW. (2009). Cystic fibrosis gene therapy: successes, failures and hopes for the future. *Expert review of respiratory medicine*, 3(4), pp. 363-71. Grimes, BR., Schindelhauer, D., McGill, NI., Ross, A., Ebersole, TA., & Cooke, HJ. (2001).

Groth, AC., & Calos MP. (2004). Phage integrases: biology and applications. *Journal of* 

Haase, SB., & Calos, MP. (1991). Replication control of autonomously replicating human

Hacein-Bey-Abina, S, Von Kalle, C., Schmidt, M, McCormack, MP., Wulffraat, N, Leboulch,

Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E.,

immunodeficiency. *New England journal of medicine*, 348(3), pp. 255-6. Hagstrom, JE., Hegge, J., Zhang, G., Noble, M., Budker, V., Lewis, DL., Herweijer, H. &

artificial microchromosomes. *Nature genetics*, 15(4), pp. 345-55.

skeletal muscle of mammalian limbs. *Molecular therapy*, 10(2), pp. 386-98. Harrington, JJ., Van Bokkelen, G., Mays, RW., Gustashaw, K., & Willard, HF. (1997).

integration. *Human gene therapy*, 17(11), pp. 1077-94.

centrometric heterochromatin. *Cell,* 99(3), pp. 259-69.

transfer into primary cells. *Methods*, 33(2), pp. 151-63.

sequences. *Nucleic acids research*, 19(18), pp. 5053-8.

therapy for SCID-X1. *Science*, 302(5644), pp. 415-9.

3(9), pp. 797-801.

*research*, 16(8), pp. 1273-9.

2(10), pp. 910-4.

*molecular biology*, 335(3), pp. 667-78.

gene therapy for cystic fibrosis requires only partial gene correction. *Gene therapy*,

Scheule, R. (2002). Development of catheter-based procedures for transducing the isolated rabbit liver with plasmid DNA. *Human gene therapy*, 13(17), pp. 2065-77. Ebersole, T., Ross, A., Clark, E., McGill, N., Schindelhauer, D., Cooke, H & Grimes, B. (2000).

Mammalian artificial chromosome formation from circular alphoid input DNA does not require telomere repeats. *Human molecular genetics*, 9(11), pp. 1623-31. Ehrhardt, A., Engler, JA., Xu, H., Cherry, A., & Kay, MA. (2006). Molecular analysis of

chromosomal rearrangements in mammalian cells after phiC31-mediated

DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. *Pharmaceutical* 

suppresses silencing of a transgene and prevents its localization close to

Chen, S., Castro-Obregon, S., Hammermann, R., Wolf, J., Muler-Hartmann, H., Nix, M., Siebenkotten, G., Kraus, G. & Lun, K. (2004). New non-viral method for gene

Stable gene expression from a mammalian artificial chromosome. *EMBO reports*,

P., (2003). LMO2-associated clonal T cell proliferation in two patients after gene

Radford, I., Villeval, JL., Fraser, C., Cabazzana-Calvo, M. & Fischer, A. (2003). A serious adverse event after successful gene therapy for X-linked severe combined

Wolf, J. (2004). A facile nonviral method for delivering genes and siRNAs to

Formation of de novo centromeres and construction of first-generation human


Non-Viral Gene Therapy Vectors Carrying Genomic Constructs 23

Masucci, M. G., & Ernberg, I. (1994). Epstein-Barr virus: adaptation to a life within the

McCarthy, V. A., & Harris, Ann. (2005). The CFTR gene and regulation of its expression.

McCarty, D. M., Young, Samuel M, & Samulski, R Jude. (2004). Integration of adeno-

Mejía, J. E., & Larin, Z. (2000). The assembly of large BACs by in vivo recombination.

Melman, A., Bar-Chama, N., McCullough, A., Davies, K., & Christ, G. (2007). Plasmid-based

Meyer, K. B., Thompson, M. M., Levy, M. Y., Barron, L. G., & Szoka, F. C. (1995).

Morishita, R., Makino, H., Aoki, M., Hashiya, N., Yamasaki, K., Azuma, J., et al. (2010).

Murisier, F., Guichard, S., & Beermann, F. (2006). A conserved transcriptional enhancer that

Muyrers, J. P., Zhang, Y., & Stewart, A. F. (2001). Techniques: Recombinogenic engineering--

Oehmig, A, Cortés, M L, Perry, K F, Sena-Esteves, M., Fraefel, C., & Breakefield, X O. (2007).

Osoegawa, K., Mammoser, A. G., Wu, C., Frengen, E., Zeng, C., Catanese, J. J., et al. (2001). A

Papapetrou, E. P., Ziros, P. G., Micheva, I. D., Zoumbos, N. C., & Athanassiadou, A. (2006).

Piechaczek, C., Fetzer, C., Baiker, A., Bode, J, & Lipps, H J. (1999). A vector based on the

Pérez-Luz, S., Abdulrazzak, H., Grillot-Courvalin, Catherine, & Huxley, Clare. (2007). Factor

Pérez-Luz, S., & Díaz-Nido, J. (2010). Prospects for the use of artificial chromosomes and

Quiñones, H. I., Savage, T. K., Battiste, J., & Johnson, J. E. (2010). Neurogenin 1 (Neurog1)

HSV/AAV amplicon vector. *Gene therapy*, 14(14), pp. 1078-91.

carrying an S/MAR element. *Gene therapy*, 13(1), pp. 40-51.

a phase I trial. *The Israel Medical Association journal*, 9(3), pp. 143-6.

expression and pharmacokinetics. *Gene therapy*, 2(7), pp. 450-60.

associated virus (AAV) and recombinant AAV vectors. *Annual review of genetics*, 38,

gene transfer for treatment of erectile dysfunction and overactive bladder: results of

Intratracheal gene delivery to the mouse airway: characterization of plasmid DNA

Phase I/IIa Clinical Trial of Therapeutic Angiogenesis Using Hepatocyte Growth Factor Gene Transfer to Treat Critical Limb Ischemia. *Arteriosclerosis, thrombosis, and* 

specifies Tyrp1 expression to melanocytes. *Developmental biology*, 298(2), pp. 644-55.

new options for cloning and manipulating DNA. *Trends in biochemical sciences*,

Integration of active human beta-galactosidase gene (100 kb) into genome using

bacterial artificial chromosome library for sequencing the complete human genome.

Gene transfer into human hematopoietic progenitor cells with an episomal vector

SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO

VIII mRNA expression from a BAC carrying the intact locus made by homologous

minichromosome-like episomes in gene therapy. *Journal of biomedicine &* 

expression in the ventral neural tube is mediated by a distinct enhancer and preferentially marks ventral interneuron lineages. *Developmental biology*, 340(2), pp.

immune system. *Trends in microbiology*, 2(4), pp. 125-30.

*Pediatric pulmonology*, 40(1), pp. 1-8.

*Genomics*, 70(2), pp. 165-70.

pp. 819-45.

*vascular biology*.

26(5), pp. 325-31.

*biotechnology*, 2010.

283-92.

*Genome research*, 11(3), pp. 483-96.

cells. *Nucleic acids research*, 27(2), pp. 426-8.

recombination. *Genomics*, 90(5), pp. 610-9.

human gene and associated regulatory elements. *Journal of cellular and molecular medicine*, 13(9A), pp. 2938-48.


Kotzamanis, George, Cheung, W., Abdulrazzak, H., Perez-Luz, S., Howe, Steven, Cooke,

Kotzamanis, G., & Huxley, C.. (2004). Recombining overlapping BACs into a single larger

Laner, A., Goussard, S., Ramalho, A. S., Schwarz, T., Amaral, M. D., Courvalin, P., et al.

Larsen, M. D. B., Griesenbach, U, Goussard, S., Gruenert, D. C., Geddes, D M, Scheule, R K,

Lipps, H J, Jenke, A. C. W., Nehlsen, K., Scinteie, M. F., Stehle, I M, & Bode, J. (2003).

Liu, F., Song, Y., & Liu, D. (1999). Hydrodynamics-based transfection in animals by systemic

Liu, Q., Perez, C. F., & Wang, Yaming. (2006). Efficient site-specific integration of large

Liu, R., Li, Yiming, Hu, R., Jin, T., Deng, S., Liang, W., et al. (2010). A site-specific genomic

Lufino, M. M. P., Manservigi, R., & Wade-Martins, Richard. (2007). An S/MAR-based

Magin-Lachmann, C., Kotzamanis, G., D'Aiuto, L., Wagner, E., & Huxley, C. (2003).

Manson, A. L., Trezise, A. E., MacVinish, L. J., Kasschau, K. D., Birchall, N., Episkopou, V.,

Manzini, S., Vargiolu, A., Stehle, Isa M, Bacci, M. L., Cerrito, M. G., Giovannoni, R., et al.

Maruyama, H., Higuchi, N., Nishikawa, Y., Hirahara, H., Iino, N., Kameda, S., et al. (2002).

*Proceedings of the National Academy of Sciences USA*, 103(47), pp. 17672-7. Martin, D. I., & Whitelaw, E. (1996). The vagaries of variegating transgenes. *BioEssays*,

vectors for in vitro and in vivo delivery. *BMC biotechnology*, 3(1), 2.

transgenes by an enhanced herpes simplex virus/adeno-associated virus hybrid

integration strategy for sustained expression of glucagon-like peptide-1 in mouse muscle for controlling energy homeostasis. *Biochemical and biophysical research* 

infectious episomal genomic DNA expression vector provides long-term regulated functional complementation of LDLR deficiency. *Nucleic acids research*, 35(15), e98. Magin-Lachmann, C, Kotzamanis, G, D'Aiuto, L, Cooke, H, Huxley, C, & Wagner, E. (2004).

In vitro and in vivo delivery of intact BAC DNA -- comparison of different

Retrofitting BACs with G418 resistance, luciferase, and oriP and EBNA-1 - new

et al. (1997). Complementation of null CF mice with a human CFTR YAC transgene.

(2006). Genetically modified pigs produced with a nonviral episomal vector.

Kidney-targeted naked DNA transfer by retrograde renal vein injection in rats.

genetically modified Escherichia coli. *Gene therapy*, 15(6), pp. 434-42. Li, Q., Harju, S., & Peterson, K. R. (1999). Locus control regions: coming of age at a decade

Chromosome-based vectors for gene therapy. *Gene*, 304, pp. 23-33.

administration of plasmid DNA. *Gene therapy*, 6(7), pp. 1258-66.

amplicon vector. *Journal of virology*, 80(4), pp. 1672-9.

methods. *Journal of gene medicine*, 6(2), pp. 195-209.

*medicine*, 13(9A), pp. 2938-48.

BAC. *BMC biotechnology*, 4, 1.

*therapy*, 12(21), pp. 1559-72.

recombineering. *Gene*, pp. 351, 29-38.

plus. Trends in genetics : TIG, 15(10), 403-8.

*communications*, 403(2), pp. 172-7.

*EMBO journal*, 16(14), pp. 4238-49.

*Human gene therapy*, 13(3), pp. 455-68..

18(11), pp. 919-23.

human gene and associated regulatory elements. *Journal of cellular and molecular* 

Howard, et al. (2005). Construction of human artificial chromosome vectors by

(2005). Bacterial transfer of large functional genomic DNA into human cells. *Gene* 

et al. (2008). Bactofection of lung epithelial cells in vitro and in vivo using a


Non-Viral Gene Therapy Vectors Carrying Genomic Constructs 25

Thyagarajan, Bhaskar, Liu, Y., Shin, S., Lakshmipathy, U., Scheyhing, K., Xue, H., et al.

Tischer, B. K., Schumacher, D., Beer, M., Beyer, J., Teifke, J. P., Osterrieder, K., et al. (2002). A

Tong, J., Lillico, S. G., Bi, M. J., Qing, T., Liu, X. F., Wang, Yuanyuan, et al. (2010). Tissue-

Tros de Ilarduya, C., Sun, Y., & Düzgüneş, N. (2010). Gene delivery by lipoplexes and polyplexes. *European journal of pharmaceutical sciences*, 40(3), pp. 159-70. Venken, K. J. T., He, Y., Hoskins, R. A., & Bellen, H. J. (2006). P[acman]: a BAC transgenic

Verma, I. M., & Weitzman, M. D. (2005). Gene therapy: twenty-first century medicine.

Voet, T., Vermeesch, J., Carens, A., Dürr, J., Labaere, C., Duhamel, H., et al. (2001). Efficient

Voigt, K., Izsvák, Z., & Ivics, Z. (2008). Targeted gene insertion for molecular medicine.

Wade-Martins, R, White, R. E., Kimura, H., Cook, P. R., & James, M. R. (2000). Stable

Wade-Martins, R., Saeki, Y., & Chiocca, E. A. (2003). Infectious delivery of a 135-kb LDLR

receptor deficiency in human cells. *Molecular therapy*, 7(5 Pt 1), pp. 604-12. Walther, W., Siegel, R., Kobelt, D., Knösel, T., Dietel, M., Bembenek, A., et al. (2008). Novel

melanoma and breast cancer. *Clinical cancer research*, 14(22), pp. 7545-53. Wang, G., Bunnell, B. A., Painter, R. G., Quiniones, B. C., Tom, S., Lanson, N. A., et al. (2005).

Wells, D J. (2004). Gene therapy progress and prospects: electroporation and other physical

Wolff, J A, Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., et al. (1990). Direct gene transfer into mouse muscle in vivo. *Science*, 247(4949 Pt 1), pp. 1465-8. Xenariou, S, Griesenbach, U, Ferrari, S., Dean, P., Scheule, R K, Cheng, S H, et al. (2006).

Xenariou, Stefania, Liang, H.-D., Griesenbach, Uta, Zhu, J., Farley, Raymond, Somerton, L.,

mouse lung. *Acta biochimica et biophysica Sinica*, 42(1), pp. 45-51.

integrase. *Stem cells,* 26(1), pp. 119-26.

*virology*, 83(Pt 10), pp. 2367-76.

N.Y.), 314(5806), pp. 1747-51.

*Genome research*, 11(1), pp. 124-36.

*USA*, 102(1), pp. 186-91.

methods. *Gene therapy*, 11(18), pp. 1363-9.

vivo. *Gene therapy*, 13(21), pp. 1545-52.

*Annual review of biochemistry*, 74, pp. 711-38.

*Journal of molecular medicine*, 86(11), pp. 1205-19. .

genomic transgene. *Nature biotechnology*, 18(12), pp. 1311-4.

*Transgenic research*.

(2008). Creation of engineered human embryonic stem cell lines using phiC31

DNA vaccine containing an infectious Marek's disease virus genome can confer protection against tumorigenic Marek's disease in chickens. *Journal of general* 

specific and expression of porcine growth hormone gene in BAC transgenic mice.

platform for targeted insertion of large DNA fragments in D. melanogaster. *Science*,

male and female germline transmission of a human chromosomal vector in mice.

correction of a genetic deficiency in human cells by an episome carrying a 115 kb

genomic locus leads to regulated complementation of low-density lipoprotein

jet-injection technology for nonviral intratumoral gene transfer in patients with

Adult stem cells from bone marrow stroma differentiate into airway epithelial cells: potential therapy for cystic fibrosis. *Proceedings of the National Academy of Sciences* 

Using magnetic forces to enhance non-viral gene transfer to airway epithelium in

et al. (2010). Low-frequency ultrasound increases non-viral gene transfer to the


Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-ping, et al. (n.d.). Fatal

Raviprakash, K., & Porter, K. R. (2006). Needle-free injection of DNA vaccines: a brief overview and methodology. *Methods in molecular medicine*, 127, pp. 83-9. Recchia, A., & Mavilio, F. (2006). Site-specific integration into the human genome: ready for

Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989).

Romero, N. B., Braun, S., Benveniste, O., Leturcq, F., Hogrel, J.-Y., Morris, G. E., et al. (2004).

Rommens, J. M., Iannuzzi, M. C., Kerem, B., Drumm, M. L., Melmer, G., Dean, M., et al.

Sarsero, J. P., Li, L., Holloway, T. P., Voullaire, Lucille, Gazeas, S., Fowler, K. J., et al. (2004).

Schedl, A., Montoliu, L., Kelsey, G., & Schütz, G. (1993). A yeast artificial chromosome

Scherer, F., Anton, M., Schillinger, U., Henke, J., Bergemann, C., Krüger, A., et al. (2002).

Sclimenti, C. R., & Calos, M P. (1998). Epstein-Barr virus vectors for gene expression and

Shen, M. H., Yang, J. W., Yang, J., Pendon, C., & Brown, W. R. (2001). The accuracy of

Smith, A. N., Wardle, C. J., & Harris, A. (1995). Characterization of DNASE I hypersensitive

Song, Y. K., Liu, F., Chu, S., & Liu, D. (1997). Characterization of cationic liposome-mediated

Srivastava, A., Lusby, E. W., & Berns, K I. (1983). Nucleotide sequence and organization of the adeno-associated virus 2 genome. *Journal of virology*, 45(2), pp. 555-64. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., et al. (2007).

clinical application? *Rejuvenation research*, 9(4), pp. 446-9.

complementary DNA. *Science*, 245(4922), pp. 1066-73.

transgenic mice. *Mammalian genome*, 15(5), pp. 370-82.

transfer. *Current opinion in biotechnology*, 9(5), pp. 476-9.

transgenic mice. *Nature*, 362(6417), pp. 258-61.

and in vivo. *Gene therapy*, 9(2), pp. 102-9.

*therapy*, 15(4), pp. 257-66.

*Cell*, 131(5), pp. 861-72.

1585-94.

*communications*, 211(1), pp. 274-81.

muscular dystrophy. *Human gene therapy*, 15(11), pp. 1065-76.

*metabolism*, 80(1-2), pp. 148-58.

*Science* ,245(4922), pp. 1059-65.

systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. *Molecular genetics and* 

Identification of the cystic fibrosis gene: cloning and characterization of

Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker

(1989). Identification of the cystic fibrosis gene: chromosome walking and jumping.

Human BAC-mediated rescue of the Friedreich ataxia knockout mutation in

covering the tyrosinase gene confers copy number-dependent expression in

Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro

segregation of human mini-chromosomes varies in different vertebrate cell lines, correlates with the extent of centromere formation and provides evidence for a trans-acting centromere maintenance activity. *Chromosoma*, 109(8), pp. 524-35. Sheyn, D., Kimelman-Bleich, N., Pelled, G., Zilberman, Y., Gazit, D., & Gazit, Z. (2008).

Ultrasound-based nonviral gene delivery induces bone formation in vivo. *Gene* 

sites in the 120kb 5' to the CFTR gene. *Biochemical and biophysical research* 

gene transfer in vivo by intravenous administration. *Human gene therapy*, 8(13), pp.

Induction of pluripotent stem cells from adult human fibroblasts by defined factors.


**2** 

*Iran* 

**Non-Viral Delivery Systems in Gene** 

**Therapy and Vaccine Development** 

*Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran* 

Gene therapy is the process of treating a particular disease through the introduction of genetic material in order to elicit a therapeutic benefit [Stone, 2010]. The defective gene of a diagnosed patient can be corrected by a number of different strategies such as "gene replacement", "gene correction", and "gene augmentation" [Katare and Aeri, 2010]. In replacement therapy, a normal gene is inserted somewhere in the genome so that its product could replace that of a defective gene. This approach may be suitable for recessive disorders, which are marked by deficiency of an enzyme or other proteins. Although, the gene functions in the genome providing an appropriate regulatory sequence, the approach may not be successful in treating dominant disorders associated with the production of an abnormal gene product, which interferes with the product of normal gene [Katare and Aeri, 2010]. Corrective gene therapy requires replacement of a mutant gene or a part of it with a normal sequence. This can be achieved by using recombinant technology. Another form of corrective therapy involves the suppression of a particular mutation by a transfer RNA that is introduced into a cell [Katare and Aeri, 2010]. In gene augmentation, introducing a normal genetic sequence into a host genome modifies the expression of mutant gene in defective cell and the defective host gene remains unaltered. In general, the gene therapy recipient cells may be germline cells or somatic cells. Germline cells therapy involves modifying the genes in germ cells which will pass these genetic changes to the future generations. Somatic cells therapy involves the insertion of genes into specific somatic cells like the bone marrow stem cells, fibroblasts, hepatocytes or mycocytes [Katare and Aeri, 2010]. This form of gene

therapy is being used at most genetic engineering laboratories throughout the world.

Clearly, gene therapy provides great opportunities for treating diseases from genetic disorders, infections and cancer [Park et al., 2006]. While the genetic mutations underlying various diseases are well understood, delivering a corrective gene to the unhealthy organs/tissues remains a remarkable challenge [Stone, 2010]. To achieve successful gene therapy, development of proper gene delivery systems could be one of the most important factors. Gene delivery systems should be designed to protect the genetic materials from premature degradation in systemic blood stream and to efficiently transfer the therapeutic genes to target cells. Intracellular delivery systems will be required for all molecules that have intracellular function. For example, nucleic acid molecules including encoding genes, oligonucleotides and RNA molecules must enter cells and target the nucleus when transcription is the target. Regardless of the molecules for delivery, a common requirement

**1. Introduction** 

Azam Bolhassani and Sima Rafati

